AbCellera Biologics Inc.
NASDAQ:ABCLBiotechnology
-$0.02 today
- Market cap
- $3.60B
- Beta
- 1.20
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.47
Volume 2.58M
Average 6.37M
ABCL Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
AbCellera Biologics Inc.NASDAQ: ABCL
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow turns positive
Q3 FY2026 free cash flow was $25.3M, compared with -$61.52M a year earlier. Trailing-twelve-month free cash flow was -$92.64M.
Context
- Free cash flow amounted to 231.7% of revenue in FY2025, down 416.7 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly free cash flow holds near $25.3M or moves back toward the trailing-twelve-month quarterly average of -$23.16M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (174.07M) USD
- Year-over-year change
- +6.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (174.07M) | +6.9% |
| FY2024 | 2024-12-31 | (186.95M) | -54.0% |
| FY2023 | 2023-12-31 | (121.38M) | -159.3% |
| FY2022 | 2022-12-31 | 204.7M | +10.0% |
| FY2021 | 2021-12-31 | 186.13M | — |
Free Cash Flow vs competitors
How ABCL compares with its peers on the latest reported figures
- ABCL's LTM Sep 2026 free cash flow of $92.64M is the smallest of the 4 companies compared; the peer median is $183.27M.
- Its year-over-year change of -39.5% is the 3rd highest of 4, against a peer median of +28.3%.
- Free cash flow amounts to 136.5% of revenue for ABCL, versus a peer median of 640.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $204.13M | +68.4% | — | 640.1% |
| LTM Mar 2026 | $183.27M | -46.9% | -16.3% | 129.7% | |
| LTM Mar 2026 | $98.51M | +28.3% | -1.2% | 5365.2% | |
| LTM Sep 2026 | $92.64M | -39.5% | — | 136.5% | |
| Peer median (excluding ABCL) | $183.27M | +28.3% | -8.7% | 640.1% | |
Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 153.46M | 158.52M | (146.4M) | (162.86M) | (146.41M) |
| Depreciation & Amortization | 17.25M | 33.1M | 30.89M | 97M | 28.82M |
| Deferred Income Tax | (2.02M) | (2.11M) | 1.96M | 0 | 0 |
| Stock-Based Compensation | 30.65M | 49.48M | 64.18M | 67.58M | 55.79M |
| Change in Working Capital | 41.67M | 29.83M | 13.23M | (25.84M) | (70.69M) |
| Accounts Receivables | 22.48M | (22.72M) | (45.93M) | (75.12M) | (55.62M) |
| Inventory | 0 | 0 | 18.25M | 0 | 0 |
| Accounts Payables | 1.4M | 1.07M | (15.1M) | 10.64M | 3.46M |
| Other Working Capital | 17.79M | 51.47M | 56.01M | 38.64M | (18.53M) |
| Other Non-Cash Items | 3.57M | 8.55M | (7.74M) | (84.44M) | 1.2M |
| Operating Cash Flow | 244.58M | 277.36M | (43.88M) | (108.56M) | (131.3M) |
| Capital Expenditures | (58.45M) | (72.66M) | (77.51M) | (78.4M) | (42.77M) |
| Acquisitions (Net) | (11.46M) | (25.68M) | (13.69M) | (19.63M) | (7.14M) |
| Purchases of Investments | (322.57M) | (781.35M) | (1.07B) | (765.09M) | (453.14M) |
| Sales of Investments | 27.61M | 510.63M | 910.94M | 948.81M | 506.07M |
| Other Investing Activities | 32.62M | 16.43M | 25.31M | 35.71M | 84.72M |
| Investing Cash Flow | (332.25M) | (352.63M) | (221.11M) | 121.41M | 87.75M |
| Debt Repayment | (951K) | 2.76M | 11.59M | 13.5M | 0 |
| Common Stock Issued | 4.62M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.55M) | (4.38M) | (1.23M) | (729K) | 14.08M |
| Financing Cash Flow | (3.89M) | (1.63M) | 10.36M | 12.77M | 14.08M |
| Effect of Forex Changes | (1.43M) | (9.6M) | 589K | (2.62M) | 1.1M |
| Net Change in Cash | (92.97M) | (86.49M) | (254.04M) | 23.01M | (28.37M) |
| Free Cash Flow | 186.13M | 204.7M | (121.38M) | (186.95M) | (174.07M) |
AbCellera Biologics Inc.
NASDAQ:ABCL
Intrinsic Alpha fair value
Locked
Current Price
$11.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.